176 related articles for article (PubMed ID: 33460998)
1. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
2. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
4. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of ALDH1A1 expression in early invasive breast cancer.
Althobiti M; El Ansari R; Aleskandarany M; Joseph C; Toss MS; Green AR; Rakha EA
Histopathology; 2020 Sep; 77(3):437-448. PubMed ID: 32369651
[TBL] [Abstract][Full Text] [Related]
7. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY
Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
9. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
10. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
11. Markers of tumor-initiating cells predict chemoresistance in breast cancer.
Gong C; Yao H; Liu Q; Chen J; Shi J; Su F; Song E
PLoS One; 2010 Dec; 5(12):e15630. PubMed ID: 21187973
[TBL] [Abstract][Full Text] [Related]
12. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder.
Keymoosi H; Gheytanchi E; Asgari M; Shariftabrizi A; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(5):2013-20. PubMed ID: 24716927
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
[TBL] [Abstract][Full Text] [Related]
15. A review of the racial heterogeneity of breast cancer stem cells.
Gyan E; Owiredu WKBA; Fondjo LA; Jackson AM; Green AR; Rahman GA
Gene; 2021 Sep; 796-797():145805. PubMed ID: 34197949
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.
Lin L; Hutzen B; Lee HF; Peng Z; Wang W; Zhao C; Lin HJ; Sun D; Li PK; Li C; Korkaya H; Wicha MS; Lin J
PLoS One; 2013; 8(12):e82821. PubMed ID: 24376586
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
